Oviva Therapeutics, A Cambrian Biopharma *Pipeco, Announces Seed Financing And Exclusive License With Massachusetts General Hospital To Develop Therapeutics To Extend Healthspan In Women

Oviva Therapeutics, Inc. (Oviva), the women's health biotech company and a Cambrian Biopharma *PipeCo, today announced an in-licensing agreement with Massachusetts General Hospital (MGH) of a family of patents, as well as $11.5 million in Seed funding, to develop first-in-class therapeutics to improve healthspan – the period of life spent in good health - in women. Oviva Therapeutics addresses the vast unmet need in women's health by expanding funding, research, and clinical development of treatments addressing female physiology, beginning with a focus on ovarian aging.